Physician profile
Parvez Memon
NPI 1225181811
$6,941.28
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $1,360 · 2021: $1,456 · 2022: $1,256 · 2023: $1,161 · 2024: $15.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.97 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,547.21 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,023.18 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $892.14 | 2019-2023 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.17 | 2019-2023 | Tradjenta, Jardiance, Trijardy Xr |
| Astrazeneca Pharmaceuticals Lp | $521.52 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $361.36 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $302.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $270.08 | 2019 | |
| Pfizer INC. | $267.43 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $177.25 | 2021 | |
| Alkermes, INC. | $104.86 | 2019-2020 | |
| Allergan, INC. | $95.69 | 2019-2020 | |
| Abbvie INC. | $90.93 | 2021-2023 | |
| Abbott Laboratories | $86.13 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company Ltd. | $85.83 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $60.23 | 2022-2023 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $58.05 | 2022 | |
| Bausch Health US, LLC | $45.12 | 2020-2021 | |
| Exact Sciences Corporation | $42.77 | 2023 | Cologuard Collection Kit |
| Melinta Therapeutics, LLC | $38.43 | 2019 | |
| Scilex Pharmaceuticals INC. | $32.22 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $28.17 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.75 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $22.71 | 2021 | |
| Philips North America LLC | $19.69 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 2021 | |
| Orexo US, INC. | $17.08 | 2019 | |
| Aytu Biopharma, INC. | $16.79 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.33 | 2022 | |
| Amarin Pharma, INC. | $11.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvez Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.